Array BioPharma (ARRY) PT Raised to $24 at Jefferies
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $4.06 -4.25%
Rating Summary:
17 Buy, 15 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 19 | Down: 9 | New: 26
Rating Summary:
17 Buy, 15 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 19 | Down: 9 | New: 26
Join SI Premium – FREE
Jefferies analyst Eun Yang raised the price target on Array BioPharma (NASDAQ: ARRY) to $24.00 (from $21.00) while maintaining a Buy rating.
Yang notes the company narrowed its Q2 net loss of strong Braftovi/Mektovi sales.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Downgrades Array Technologies (ARRY) to Neutral
- Desjardins Reiterates Buy Rating on Cambria Gold Mines Inc (CAMB:CN)
- California Resources (CRC) PT Lowered to $91 at Stephens
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Analyst PT ChangeRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
